ALEXANDRIA, Va. – Co-sponsors announced today four key studies from the 2014 Genitourinary Cancers Symposium that will be featured in an embargoed presscast for reporters on Tuesday, January 28, 2014, from 12:00-1:30 PM (EST).
Researchers will present the following studies during the Presscast:
- Prostate Cancers
- Results from a randomized, double-blind, phase III trial evaluating enzalutamide in men with metastatic castration-resistant prostate cancer who had not previously received chemotherapy (Abstract #LBA1^)
- Findings from a Scandinavian Prostate Cancer Group VII trial analyzing 10- and 15-year prostate cancer-specific survival in patients with nonmetastatic high-risk prostate cancer randomized to lifelong hormone treatment alone or combined with radiotherapy (Abstract #4)
- Renal Cell Cancers
- A retrospective study investigating the impact of a common hypertension drug on survival rates of patients with metastatic renal cell cancer (Abstract #437)
- GU Clinical Trials
- A literature review on the early termination of genitourinary cancer clinical trials (Abstract #288)
Celebrating its 10th year, the Symposium will feature more than 500 abstracts on the latest strategies in prevention, screening, diagnosis and treatment of prostate, renal, testicular and urothelial cancers. This year’s meeting will be held January 30-February 1, 2014, at the San Francisco Marriott Marquis. On-site facilities for reporters will include a working newsroom and access to leading genitourinary cancers experts.
Three leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Urologic Oncology.
Registration and Housing: Instructions on how to register and reserve housing and/or participate in the January 28 Presscast for the 2014 Genitourinary Cancers Symposium are available at www.asco.org/GUpresskit. For further assistance please contact Kate Blackburn at email@example.com or 571-483-1379 or Kelly Baldwin at firstname.lastname@example.org or 571-483-1365.
# # #